Efficacy of Lactobacillus reuteri as a probiotic for the control of Cryptosporidium parvum infection was evaluated in C57BL/6 female mice that were immunosuppressed by intraperitoneal inoculation with the LP-BM5 leukemia virus. Four months after inoculation, mice developed lymphadenopathy, splenomegaly, and susceptibility to C. parvum infection. After daily prefeeding with L. reuteri (10 8 cfu/day) for 10 days, mice were challenged with 6.5 x 10 6 C. parvum oocysts and fed L. reuteri during the entire study. Mice supplemented with L. reuteri and challenged with C. parvum cleared parasite loads from the gut epithelium. However, unsupplemented animals developed persistent cryptosporidiosis and shed high levels of oocysts in the feces. L. reuteri feeding increased its colonization of the intestinal tract, which was inversely related to the fecal shedding of oocysts. These findings suggest that L. reuteri may help prevent C. parvum infection in immunodeficient subjects.
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Cryptosporidium parvum causes diarrhea and mortality in humans and young animals with an undeveloped or suppressed immune system [1] . In the immunocompetent host, cryptosporidiosis is self-limiting; however, C. parvum infection of immunocompromised persons, including AIDS patients, results in persistent cryptosporidiosis accompanied by weight loss, diarrhea, and dehydration [2] . Although C. parvum has not been identified as a direct cause of death, it may accelerate death by inducing severe malnutrition and dehydration [1, 2] . Treatment consists of fluid and electrolyte replacement. Unfortunately, no clinical therapy has been proven efficacious for the control of cryptosporidiosis.
Beneficial therapy may involve probiotic agents, defined as live microorganism(s) that beneficially affect the host by improving the properties of the indigenous microbiota when consumed [3] . This approach is based on observations that intestinal microbiota provide protection against various diseases. For example, germ-free animals are more susceptible to C. parvum infection than are their conventional counterparts with com-plete gut flora [4] . Positive prophylactic effects of probiotic organisms, including lactic acid bacteria such as lactobacilli, streptococci, and bifidobacteria, have been reported [3] . It is hypothesized that consumption of viable intestinal Lactobacillus organisms will hasten the return of the intestinal microbiota to a favorable state. One microorganism of particular interest is Lactobacillus reuteri, a normal gastrointestinal inhabitant of humans and animals. Glycerol metabolism by L. reuteri enhances microbial excretion of the metabolic intermediate, 3-hydroxypropionaldehyde (reuterin), which has been demonstrated to have antimicrobial activity against various microorganisms [5, 6] and possibly C. parvum. This antimicrobial activity may aid in the survival of L. reuteri in the gastrointestinal tract of the host.
Murine AIDS (MAIDS) provides a useful animal model for studies of cryptosporidiosis and other opportunistic infections during immunodeficient states. This animal model has several advantages over other animal AIDS models in terms of costeffectiveness, a relatively short onset ofthe disease, and clinical conditions that parallel those observed in human AIDS, including susceptibility to opportunistic infections [7 -9] . Our study was conducted to determine the ability of L. reuteri to prevent C. parvum infection in immunosuppressed mice and has potential implications for therapy in human AIDS.
Materials and Methods
Animals. Female C57BL/6 mice (3-4 weeks old) were purchased from Harlan Sprague-Dawley (Indianapolis). Mice were housed (5/cage) in a microisolator unit with an air filtration system at Tuskegee University Central Animal Facility (maintained at 20-22°C, 60%-80% relative humidity, and 12-h light-dark cycle). Animals had ad libitum access to water and mouse chow (Purina, St. Louis).
Inoculation ofmice with LP-BM5. Mice were inoculated intraperitoneally with 0.30 mL of LP-BM5 murine leukemia virus (MuLV) that had an ecotropic titer of 4.5 10glO pfu/rnL in an XC cell line (ATCC CCL 165). The stock of MuLV was a gift of R. R. Watson (University of Arizona School of Medicine, Tucson).
Cryptosporidium inocula. Sterilized oocysts of C. parvum inocula, purified from experimentally infected calves as described [10] , were a gift of 1. A. Harp (National Animal Disease Center, Ames, IA).
Preparation of L. reuteri bacteria. Two mouse isolates of L. reuteri from the stomach (strain 4000) and small intestine (strain 4020) were obtained from BioGaia Biologics (Raleigh, NC). The L. reuteri strains were grown separately and then equal colonyforming units from each strain were pooled to a final concentration of 5 X 10 8 cfu/mL. Stock L. reuteri was supplied as frozen preparations in 0.1 % peptone water for inoculation of mice.
Experimental design. In total, 40 C57BL/6 female mice (10 mice/group) were randomly assigned to one of four treatments (A-D) 4 months after LP-BM5 inoculation. The study was divided into a 10-day priming phase, during which 20 mice (groups C and D) were gavaged daily with L. reuteri (l08 cfu in 0.2 mL) or PBS (groups A and B), and an experimental phase of continued PBS and L. reuteri supplementation. Fecal samples (3-4 pellets) were collected on days 0 (baseline), 4, and 7 for total Lactobacillus species and L. reuteri enumeration as described [11] . On day 10, fecal pellets were collected from all mice for the detection of C. parvum oocysts as described [7] and enumeration of total Lactobacillus species and L. reuteri. The experimental phase was initiated on day 11 of the study, when mice (groups B and D) were challenged with 6.5 X 10 6 C. parvum oocysts in 0.2 mL of sterilized PBS. Fecal samples were collected on days 17 and 25 for L. reuteri, Lactobacillus species, and C. parvum enumeration.
On day 26, mice were sacrificed by ether inhalation, and the abdominal cavities were surgically opened to expose the gastrointestinal tract. Then 1-2 em of the proximal stomach, distal ileum, and colon were removed from each mouse and fixed in 10% phosphate-buffered formalin (pH 7.4) for enumeration of C. parvum burden on the gut epithelium as described [7] . Ileal infection was reported as number of oocysts per centimeter of intestinal cylinder. Data points for mice that had L. reuteri levels below the detection limit (5 X 10 3 cfu/g of wet feces) were conservatively substituted with 5 X 10 3 (3.7 ]OglO) cfu/g of wet feces for statistical analysis. Statistical analysis. Data were analyzed using a nested analyses of variance (ANOVA) model with a main effect of treatment (groups A-D) and a nested effect (cage within treatment). A Shapiro-Wilk test was further used to test the residual data from the nested ANOVA for assumption of normality. Treatment means were considered significant if they were different from each other at the 5% level of probability when compared by Tukey's honestly significant differences.
Results
Feed, water consumption, and body weight. Feed intake was similar among all treatment groups (~3 g/mouse/day). However, animals given supplemental L. reuteri had higher water intakes than those receiving PBS (4.85 vs. 3.90 rnL/ mouse/day). Change in body weight was similar across all treatments (data not shown). Shedding of C. parvum. No C. parvum oocysts were detected in feces of mice not challenged with C. parvum (groups A and C). However, mice challenged with the parasite (groups B and D) developed persistent cryptosporidiosis (table 1) . Infection with C. parvum without L. reuteri supplementation (group B) increased (P < .05) shedding of oocysts at 7 and 14 days after infection. While there was no difference (P > .05) in oocyst shedding between groups Band D at 7 days after infection, shedding was reduced (P < .05) at 14 days after challenge in mice fed supplemental L. reuteri (group D). Furthermore, Cryptosporidium parasite loads were cleared from the intestinal epithelium (specifically the distal ileum) of group D mice. In addition, no parasites were detected in the intestinal villi of uninfected mice (groups A and C). However, significant (P < .05) parasite burdens were detected in the intestines of mice (group B) infected with C. parvum alone (table 1). Contrary to the colonization of the distal ileum, no C. parvum parasites were observed in stomach or colon tissues of challenged mice.
Lactobacillus colonization. Fecal levels of total Lactobacillus species were similar across all treatments for the duration ofthe study (table 2) . Only on day 17 were statistically different levels found (group B > A). The level of L. reuteri in the feces was similar (P > .05) across all treatments at day 0 (baseline). On day 4, treatment groups C and D had higher (P < .05) levels of L. reuteri and tended to have higher levels on day 7. However, on days 10, 17, and 25, all mice except group B consistently shed high levels of L. reuteri in feces.
Discussion
Infection of mice with LP-BM5 induced MAIDS with progressive splenomegaly, lymphadenopathy, and increased susceptibility to C. parvum similar to human AIDS, as reviewed * 10 mice/group (5 mice/cage). Groups C and D were supplemented with 1. reuteri; groups B and D were challenged with C. parvum.
ttll Values within same column with unlike superscript symbols differ (P < .05). Data were analyzed by analysis of variance, Tukey's honestly significant differences test.
by Watson [9] . Unlike human AIDS, which is associated with weight loss and sometimes life-threatening diarrhea, MAIDS in this study did not manifest these conditions. Fecal levels of total Lactobacillus organisms were similar across all experimental treatments over all time points. Maximum colonization (as measured in feces) by Lactobacillus species (l09 cfu/g) suggests possible mechanisms controlling the microbiota populations in the intestinal tract. Similar results have been noted by others in studies with supplementallactobacilli feeding [11, 12] . However, it is difficult to know if the levels enumerated in fecal samples mimic the levels within the distal ileum, where lactobacilli are most dominant.
1. reuteri levels were similar among treatment groups at baseline, although 1. reuteri was enumerated from several animals prior to their receiving it as supplementation. This result is not surprising, because 1. reuteri is a ubiquitous organism of the small intestine of animals and humans [13] . Fecal levels tended to rise in mice supplemented with 1. reuteri throughout the study. In addition, 1. reuteri levels tended to rise in group A mice (PBS-supplemented, no C. parvum challenge). The progressive immunodeficiency that developed in these animals after LP-BM5 infection might have facilitated the intestinal growth of indigenous 1. reuteri in all animals.
There was an inverse relationship between 1. reuteri numbers and clearance of C. parvum parasites from the intestinal tract in treatment groups Band D. Thus, mice infected with C. parvum and concomitantly fed 1. reuteri (group D) cleared parasite loads from the intestinal tract. However, mice infected with C. parvum alone (group B) shed oocysts persistently but were less colonized by 1. reuteri (tables 1, 2) .
The mechanisms by which 1. reuteri inhibits the growth of C. parvum are not known. It is speculated that 1. reuteri may inhibit the growth of other bacteria and parasites in the gut microbiota by the secretion of inhibitory products, including reuterin, which has antimicrobial activity against potential pathogens such as Salmonella, Listeria, Clostridium, and Escherichia species [5, 6] . The inhibitory effects of this by-product of1. reuteri may adversely affect the survival of several intestinal parasites, including C. parvum, in this MAIDS model.
In addition, 1. reuteri may compete for binding sites on the gut epithelium, inhibiting C. parvum attachment and proliferation. 1. reuteri strains isolated from mice were utilized in this study because it has been shown that 1. reuteri strains are species-specific. For example, Molin et al. [14] fed 1 human isolate and I rat isolate to rats and found that the rat isolate colonized the intestinal mucosa while the human isolate did not. This finding supports the hypothesis that the mucosal colonization ability of lactobacilli is host-specific [15] . Furthermore, it has been suggested that the normal intestinal flora mediate a nonspecific immune response, enhancing resistance to C. parvum infection [4] . In conclusion, this study provides evidence that 1. reuteri may be beneficial for the prophylactic treatment of cryptosporidiosis in immunocompromised subjects.
